Argos Therapeutics Overview
- Year Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Argos Therapeutics General Information
Description
Developer of personalized immunotherapies designed for the treatment of cancer and infectious diseases. The company utilizes proprietary technology for developing rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and dendritic cell-based immunotherapy for the treatment of human immunodeficiency virus, enabling doctors to improve the patient's immune response to their specific condition.
Contact Information
Website
www.argostherapeutics.com(Operating Subsidiary)
Corporate Office
- 4233 Technology Drive
- Durham, NC 27704
- United States
Corporate Office
- 4233 Technology Drive
- Durham, NC 27704
- United States
Argos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 20. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 19. Later Stage VC | 01-Jun-2021 | Cancelled | Clinical Trials - Phase 2 | |||
| 18. Later Stage VC (Series A) | 04-Nov-2020 | Completed | Clinical Trials - Phase 2 | |||
| 17. Merger/Acquisition | 13-Feb-2019 | Completed | Bankruptcy: Admin/Reorg | |||
| 16. Bankruptcy: Admin/Reorg | 30-Nov-2018 | Completed | Bankruptcy: Admin/Reorg | |||
| 15. PIPE | 28-Jul-2016 | Completed | Generating Revenue | |||
| 14. Secondary Transaction - Open Market | 23-Mar-2016 | Completed | Generating Revenue | |||
| 13. PIPE | 14-Apr-2015 | Completed | Clinical Trials - Phase 2 | |||
| 12. IPO | 07-Feb-2014 | $45M | $274M | Completed | Clinical Trials - Phase 2 | |
| 11. Later Stage VC (Series E) | 20-Nov-2013 | $60M | $229M | Completed | Clinical Trials - Phase 2 |
Argos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 18,500,000 | $0.001000 | 8% | $1.76 | $0.56 | 1x | $22.63 | 1.5% |
| Series A | 1,200,000 | $0.001000 | 8% | $1 | $0.32 | 1x | $22.63 | 0.06% |
Argos Therapeutics Comparisons
Industry
Financing
Details
Argos Therapeutics Competitors (69)
One of Argos Therapeutics’s 69 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Arno Therapeutics | Formerly VC-backed | Flemington, NJ | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA | ||||
| Pure MHC | Formerly VC-backed | Austin, TX |
Argos Therapeutics Patents
Argos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021205502-A1 | Methods of treating tumors | Inactive | 10-Jan-2020 | ||
| CA-3162074-A1 | Methods of treating tumors | Pending | 10-Jan-2020 | ||
| EP-4087601-A2 | Methods of treating tumors | Inactive | 10-Jan-2020 | ||
| US-20230061319-A1 | Methods of treating tumors | Inactive | 10-Jan-2020 | ||
| WO-2021142305-A2 | Methods of treating tumors | Inactive | 10-Jan-2020 | A61K40/46 |
Argos Therapeutics Signals
Argos Therapeutics Former Investors (35)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ABN AMRO Bank | Investment Bank | Minority | ||
| Ascenion | Accelerator/Incubator | |||
| BD Ventures | Corporate Venture Capital | Minority | ||
| Buenafortuna Capital | Venture Capital | Minority | ||
| Cordova Ventures | Venture Capital | Minority |
Argos Therapeutics Acquisitions (1)
Argos Therapeutics’s most recent deal was a Merger/Acquisition with Formula Pharmaceuticals. The deal was made on 16-Jan-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Formula Pharmaceuticals | 16-Jan-2020 | Merger/Acquisition | Drug Discovery |
Argos Therapeutics FAQs
-
When was Argos Therapeutics founded?
Argos Therapeutics was founded in 1997.
-
Where is Argos Therapeutics headquartered?
Argos Therapeutics is headquartered in Durham, NC.
-
What is the size of Argos Therapeutics?
Argos Therapeutics has 15 total employees.
-
What industry is Argos Therapeutics in?
Argos Therapeutics’s primary industry is Drug Discovery.
-
Is Argos Therapeutics a private or public company?
Argos Therapeutics is a Private company.
-
What is Argos Therapeutics’s current revenue?
The current revenue for Argos Therapeutics is .
-
How much funding has Argos Therapeutics raised over time?
Argos Therapeutics has raised $45M.
-
Who are Argos Therapeutics’s investors?
ABN AMRO Bank, Ascenion, BD Ventures, Buenafortuna Capital, and Cordova Ventures are 5 of 35 investors who have invested in Argos Therapeutics.
-
Who are Argos Therapeutics’s competitors?
Inovio Pharmaceuticals, Arno Therapeutics, Centrose, Iovance Biotherapeutics, and Pure MHC are some of the 69 competitors of Argos Therapeutics.
-
Who acquired Argos Therapeutics?
Argos Therapeutics was acquired by Genexine and Poongjeon Pharmacy.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process